Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if RAD001 (everolimus) helps improve the standard
treatment of XELOX-A (bevacizumab, oxaliplatin, capecitabine) in advanced solid tumors.